X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (100816) 100816
Patent (33833) 33833
Publication (7612) 7612
Newspaper Article (4953) 4953
Book Review (848) 848
Magazine Article (688) 688
Book Chapter (610) 610
Newsletter (589) 589
Conference Proceeding (445) 445
Trade Publication Article (354) 354
Dissertation (289) 289
Web Resource (162) 162
Book / eBook (132) 132
Government Document (21) 21
Reference (11) 11
Paper (9) 9
Data Set (8) 8
Journal / eJournal (5) 5
Streaming Video (4) 4
Transcript (2) 2
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (46049) 46049
animals (39629) 39629
male (35086) 35086
index medicus (24924) 24924
human necessities (24423) 24423
sports (24042) 24042
games (24025) 24025
amusements (24018) 24018
toys, e.g. tops, dolls, hoops, building blocks (23898) 23898
female (23693) 23693
calcium channel blockers - pharmacology (20544) 20544
rats (18854) 18854
pharmacology & pharmacy (14936) 14936
middle aged (14407) 14407
performing operations (12168) 12168
transporting (12168) 12168
calcium channel blockers - therapeutic use (11757) 11757
aged (11611) 11611
hypertension (10364) 10364
adult (10282) 10282
cardiac & cardiovascular systems (10013) 10013
hoisting (9944) 9944
lifting (9944) 9944
hauling (9943) 9943
capstans (9936) 9936
hoists (9936) 9936
tackles, e.g. pulley blocks (9936) 9936
winches (9936) 9936
hypertension - drug therapy (9367) 9367
heart failure (8744) 8744
beta blockers (8469) 8469
in vitro techniques (7976) 7976
neurosciences (7555) 7555
dose-response relationship, drug (7538) 7538
calcium - metabolism (7490) 7490
blood pressure - drug effects (7345) 7345
mice (6666) 6666
peripheral vascular disease (6162) 6162
treatment outcome (6060) 6060
beta-blockers (5844) 5844
mortality (5838) 5838
rats, sprague-dawley (5738) 5738
time factors (5656) 5656
adrenergic beta-antagonists - therapeutic use (5564) 5564
physiology (5439) 5439
antihypertensive agents - therapeutic use (5426) 5426
angiotensin-converting enzyme inhibitors - therapeutic use (5210) 5210
drug therapy (5003) 5003
cells, cultured (4985) 4985
calcium channel blockers (4973) 4973
risk factors (4916) 4916
potassium channel blockers - pharmacology (4687) 4687
rats, wistar (4673) 4673
research (4671) 4671
patch-clamp techniques (4468) 4468
angiotensin ii type 1 receptor blockers - therapeutic use (4207) 4207
nifedipine - pharmacology (4171) 4171
analysis (4162) 4162
drug therapy, combination (4144) 4144
biochemistry & molecular biology (4066) 4066
medicine, general & internal (3863) 3863
hypertension - physiopathology (3838) 3838
calcium (3661) 3661
care and treatment (3641) 3641
blood pressure (3591) 3591
blood-pressure (3530) 3530
membrane potentials - drug effects (3420) 3420
heart rate - drug effects (3331) 3331
calcium channel blockers - administration & dosage (3318) 3318
nifedipine (3238) 3238
verapamil - pharmacology (3238) 3238
angiotensin ii type 1 receptor blockers - pharmacology (3166) 3166
adrenergic beta blockers (3142) 3142
electrocardiography (3076) 3076
electrophysiology (3072) 3072
cardiology (3024) 3024
potassium channel blockers (2988) 2988
calcium channels (2979) 2979
health aspects (2954) 2954
double-blind method (2953) 2953
therapy (2933) 2933
kinetics (2918) 2918
expression (2904) 2904
rabbits (2887) 2887
angiotensin (2863) 2863
medicine & public health (2852) 2852
disease models, animal (2851) 2851
aged, 80 and over (2831) 2831
cells (2830) 2830
calcium channel blockers - adverse effects (2808) 2808
lighting (2795) 2795
heating (2794) 2794
mechanical engineering (2793) 2793
weapons (2789) 2789
blasting (2788) 2788
neurons - drug effects (2751) 2751
calcium-channel blockers (2730) 2730
urology & nephrology (2700) 2700
heart (2674) 2674
inhibition (2674) 2674
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (107) 107
UTL at Downsview - May be requested (12) 12
Online Resources - Online (11) 11
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - May be requested in 6-10 wks (1) 1
Robarts - Stacks (1) 1
Royal Ontario Museum - Far Eastern (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (101055) 101055
German (25193) 25193
French (15629) 15629
Japanese (2163) 2163
Russian (1894) 1894
Danish (1235) 1235
Swedish (780) 780
Chinese (704) 704
Norwegian (553) 553
Spanish (443) 443
Polish (228) 228
Korean (213) 213
Portuguese (199) 199
Italian (159) 159
Czech (137) 137
Ukrainian (125) 125
Hungarian (100) 100
Slovak (68) 68
Dutch (64) 64
Romanian (54) 54
Turkish (52) 52
Finnish (32) 32
Bulgarian (20) 20
Croatian (20) 20
Hebrew (19) 19
Serbian (19) 19
Lithuanian (9) 9
Persian (7) 7
Slovenian (7) 7
Bosnian (5) 5
Arabic (3) 3
Icelandic (2) 2
Belarusian (1) 1
Catalan (1) 1
Greek (1) 1
Norwegian Bokmål (1) 1
Thai (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hypertension, ISSN 0194-911X, 07/2015, Volume 66, Issue 1, pp. 183 - 189
Conflicting data on the relationship between antihypertensive medications and falls in elderly people may lead to inappropriate undertreatment of hypertension... 
aged | blood flow velocity | angiotensin-converting enzyme inhibitors | antihypertensive agents | calcium channel blockers | POPULATION | METAANALYSIS | INCREASES | RISK | HYPERTENSIVE PATIENTS | AUTOREGULATION | HEMODYNAMICS | PRESSURE | PERIPHERAL VASCULAR DISEASE | PEOPLE | CEREBRAL-BLOOD-FLOW | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Calcium Channel Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Calcium Channel Blockers - therapeutic use | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Dose-Response Relationship, Drug | Adrenergic beta-Antagonists - pharmacology | Accidental Falls - prevention & control | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Adrenergic beta-Antagonists - adverse effects | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Blood Pressure - drug effects | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Diuretics - administration & dosage | Disease Susceptibility | Cerebrovascular Circulation - drug effects | Comorbidity | Diuretics - pharmacology | Accidents, Home - prevention & control | Antihypertensive Agents - therapeutic use | Calcium Channel Blockers - pharmacology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Diabetes Mellitus - epidemiology | Calcium Channel Blockers - administration & dosage | Diuretics - therapeutic use | Aged | Cognition Disorders - epidemiology | Diuretics - adverse effects | Life Sciences | Human health and pathology
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 04/2013, Volume 20, Issue 10, pp. 1241 - 1285
Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system.... 
ASIC | TRP | Central nervous system | P2X | KCNQ | NMDA | CNS | Ion channels | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | GATED SODIUM-CHANNELS | SUBTYPE-SELECTIVE AGONIST | D-ASPARTATE RECEPTOR | ion channels | ACID-SENSING ION-CHANNEL-1 | central nervous system | GLYCINE ANTAGONIST GV150526 | TARANTULA TOXIN PSALMOTOXIN-1 | TRAUMATIC BRAIN-INJURY | ISCHEMIC CELL-DEATH | PHARMACOLOGY & PHARMACY | PERIPHERAL NEUROPATHIC PAIN | TRANSGENIC MOUSE MODEL | Ligand-Gated Ion Channels - antagonists & inhibitors | Transient Receptor Potential Channels - antagonists & inhibitors | Calcium Channels - metabolism | Humans | Calcium Channel Blockers - therapeutic use | Potassium Channel Blockers - therapeutic use | Sodium Channel Blockers - pharmacology | Calcium Channel Blockers - pharmacology | Ion Channels - antagonists & inhibitors | Potassium Channels - metabolism | Animals | Ion Channels - metabolism | Sodium Channels - chemistry | Calcium Channels - chemistry | Central Nervous System Diseases - drug therapy | Sodium Channels - metabolism | Calcium Channel Blockers - chemistry | Sodium Channel Blockers - therapeutic use | Potassium Channels - chemistry | Sodium Channel Blockers - chemistry | Transient Receptor Potential Channels - metabolism | Ligand-Gated Ion Channels - metabolism | Potassium Channel Blockers - chemistry | Potassium Channel Blockers - pharmacology
Journal Article
Annual Review of Pharmacology and Toxicology, ISSN 0362-1642, 1/2015, Volume 55, Issue 1, pp. 333 - 352
The four major classes of antihypertensive drugs-diuretics, β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors (including... 
angiotensin-converting enzyme inhibitors | β-blockers | angiotensin receptor blockers | calcium channel blockers | diuretics | hypertension | Angiotensin-converting enzyme inhibitors | Hypertension | Diuretics | Calcium channel blockers | Angiotensin receptor blockers | CLINICAL-PHARMACOLOGY | CARDIOVASCULAR EVENTS | HEART-FAILURE | beta-blockers | CONVERTING ENZYME-INHIBITORS | BLOOD-PRESSURE REDUCTION | CANADIAN HYPERTENSION | CALCIUM-CHANNEL BLOCKERS | ANGIOTENSIN-RECEPTOR BLOCKERS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CORONARY-ARTERY-DISEASE | Adrenergic beta-Antagonists - classification | Angiotensin-Converting Enzyme Inhibitors - classification | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Treatment Outcome | Structure-Activity Relationship | Antihypertensive Agents - classification | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Antihypertensive Agents - chemistry | Animals | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin II Type 1 Receptor Blockers - classification | Hypertension - complications | Calcium Channel Blockers - classification | Diuretics - therapeutic use | Blood Pressure - drug effects | Molecular Structure | Diuretics - classification | Adrenergic beta-Antagonists - therapeutic use | Index Medicus
Journal Article
Journal Article
Molecular Carcinogenesis, ISSN 0899-1987, 08/2018, Volume 57, Issue 8, pp. 997 - 1007
Recent studies suggest that the β‐blocker drug carvedilol prevents skin carcinogenesis but the mechanism is unknown. Carvedilol is one of a few β‐blockers... 
alprenolol | biased β‐blocker | carcinogenesis | β‐blocker | JB6 P+ cells | β-blocker | biased β-blocker | SURVIVAL | blocker | ACTIVATION | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | BREAST-CANCER | THERAPY | ONCOLOGY | PATHWAY | POPULATION-BASED COHORT | biased -blocker | C-JUN | BETA-BLOCKER USE | JB6 CELLS | Melanoma - metabolism | Humans | Carvedilol - pharmacology | Epidermal Growth Factor - metabolism | Male | Melanoma - pathology | Mice, SCID | Carcinogenesis - metabolism | Carcinogenesis - drug effects | Carcinogenesis - pathology | Adrenergic beta-Antagonists - pharmacology | Animals | Melanoma - prevention & control | Mitogen-Activated Protein Kinase 3 - metabolism | Proto-Oncogene Proteins c-jun - metabolism | HEK293 Cells | Mice, Inbred NOD | Phosphorylation - drug effects | Carvedilol - therapeutic use | Anticarcinogenic Agents - pharmacology | Proteome - metabolism | Adrenergic beta-Antagonists - therapeutic use | Anticarcinogenic Agents - therapeutic use | Mitogen-Activated Protein Kinase 1 - metabolism | Prevention | Epidermal growth factor | Cancer | Translocation | Phosphorylation | Fractionation | Transformation | Elk | Xenotransplantation | Melanoma | Antibodies | Extracellular signal-regulated kinase | Arrestin | Carcinogenesis | Nuclear transport | Anticancer properties | Ribosomal protein S6 kinase | Signaling | Carcinogens | Xenografts | Antitumor activity | Skin | Inhibition | Index Medicus
Journal Article
Toxicological Sciences, ISSN 1096-6080, 03/2017, Volume 156, Issue 1, pp. 25 - 38
Drug-induced proarrhythmia is a major safety issue in drug development. Developing sensitive in vitro assays that can predict drug-induced cardiotoxicity in... 
Drug-induced proarrhythmia | iPSC-CMs | Batch variations | ACTION-POTENTIALS | TORSADES-DE-POINTES | DOFETILIDE | CONTRACTILITY | drug-induced proarrhythmia | PROLONGATION | LONG-QT SYNDROME | VENTRICULAR MYOCYTES | MATURATION | IMPEDANCE | TOXICOLOGY | batch variations | RISK-ASSESSMENT | Arrhythmias, Cardiac - chemically induced | Drug Evaluation, Preclinical - economics | Calcium Channel Blockers - adverse effects | Anti-Arrhythmia Agents - pharmacology | Humans | Potassium Channel Blockers - antagonists & inhibitors | Toxicity Tests, Acute - methods | Potassium Channel Blockers - adverse effects | Arrhythmias, Cardiac - pathology | Shal Potassium Channels - genetics | Kv1.5 Potassium Channel - genetics | Toxicity Tests, Acute - economics | Induced Pluripotent Stem Cells - cytology | Voltage-Gated Sodium Channel Blockers - adverse effects | Potassium Channel Blockers - pharmacology | Induced Pluripotent Stem Cells - metabolism | Arrhythmias, Cardiac - metabolism | Induced Pluripotent Stem Cells - pathology | Cell Line | Drug Evaluation, Preclinical - methods | Reproducibility of Results | Induced Pluripotent Stem Cells - drug effects | Myocytes, Cardiac - cytology | Antioxidants - pharmacology | Calcium Channel Blockers - pharmacology | Gene Expression Regulation - drug effects | Myocytes, Cardiac - pathology | Shal Potassium Channels - metabolism | Calcium Channels, L-Type - genetics | Myocytes, Cardiac - drug effects | Cell Differentiation - drug effects | Kv1.5 Potassium Channel - metabolism | Calcium Channel Blockers - chemistry | Myocytes, Cardiac - metabolism | Voltage-Gated Sodium Channel Blockers - pharmacology | Calcium Channels, L-Type - metabolism | Kinetics | Electrophysiological Phenomena - drug effects
Journal Article
Journal Article